Yes, Certis is well-versed in testing the efficacy of ADCs. This includes screening of monoclonal antibody (MAb) binding to their tumor-specific antigen (TSA) specificity, cross-reactivity and avidity, immune-modulatory and immunological cell death induced by ADCs, target modulation/pharmacodynamic read out, on-target/off-tumor reactivity, anti-drug antibody screen, studying mechanisms of resistance, and more for combinational therapy.